<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004498</url>
  </required_header>
  <id_info>
    <org_study_id>199/14290</org_study_id>
    <secondary_id>UPSM-FDR001529</secondary_id>
    <nct_id>NCT00004498</nct_id>
  </id_info>
  <brief_title>Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety, feasibility, and potential efficacy of intravascular adenoviral&#xD;
      vector mediated gene transfer in the liver in adults with partial ornithine transcarbamylase&#xD;
      deficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a dose escalation study. Patients undergo a femoral arterial&#xD;
      placement of a hepatic intraarterial catheter. Patients then receive adenoviral vector&#xD;
      mediated gene transfer intravascularly over 30 minutes.&#xD;
&#xD;
      Cohorts of 3 patients each receive escalating doses of adenoviral vector until the maximum&#xD;
      tolerated dose is determined.&#xD;
&#xD;
      Patients are followed at 3, 5, 7, 8, 15, and 29 days, at 2 months, and then every 3 months&#xD;
      thereafter.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 1998</start_date>
  <completion_date>September 2000</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>21</enrollment>
  <condition>Ornithine Transcarbamylase Deficiency Disease</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Adenoviral Vector-Mediated Gene Transfer</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Diagnosis of partial ornithine transcarbamylase deficiency Female heterozygote with&#xD;
             abnormal allopurinol challenge or underlying defect in either N15 urea or N15&#xD;
             glutamine OR Male with childhood/adulthood onset OR Family history of 2 affected&#xD;
             children&#xD;
&#xD;
          -  Stable for at least 1 month prior to study&#xD;
&#xD;
          -  Plasma ammonium levels less than 50 micromoles&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Concurrent alternate pathway therapy to control hyperammonemia allowed&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Hepatic: No history of liver disease&#xD;
&#xD;
          -  Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use&#xD;
             effective contraception No high level of neutralizing antibodies to the adenovirus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven E. Raper</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <verification_date>February 2000</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>ornithine transcarbamylase deficiency</keyword>
  <keyword>rare disease</keyword>
  <keyword>urea cycle disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

